Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Флупиртин (Катадолон) – нестандартный подход в терапии боли
Флупиртин (Катадолон) – нестандартный подход в терапии боли
В.В.Алексеев, А.П.Рачин, Е.В.Подчуфарова. Флупиртин (Катадолон) – нестандартный подход в терапии боли. Consilium Medicum. Неврология (Прил.). 2009; 2: 50-53.
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Рачин А.П. Десять доказательств успешного применения флупиртина (Катадолона) при болях в нижней части спины. Лечение нервных болезней. 2007; 8, 2 (21): 35–9.
2. Block F, Pergande G, Schwarz M. Flupirtine reduced funcional deficits and neuronal damage after global ischaemia in rats. Brain Res 1997; 754: 279–84.
3. Engel J. Flupirtine – a new centrally acting analgesic with unique chemical structure. Postgrad Med J 1987; 63 (Suppl. 3): 15–7.
4. Friedel НА, Fitton A. Flupirtine. A review of its farmacological properties and therapeutic efficacy in pain states. Dmgs 1993; 45: 548–69.
5. Komuber J et al. Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels. J Neural Transm 1999; 106: 857–67.
6. Mueller-Schwefe G. Flupirtine in Acute and Chronic Pain Associated with Muscle Tenseness. Results of a Postmarketing Surveillance Study. Fortschr Med 2003; 121: 3–10.
7. Muller WEG et al. Protection offlupirtine on p-amyloid-induced apoptisis in neuronal cells in vitro. J Neurochem 1997; 68: 2371–7.
8. Osbome NN et al. Protection of rabbit retina from ischemic injury by flupirtine. Invest. Ophtalm 1996; 37: 274–80.
9. Schuster G, Schwarz M et al. Flupirtine: A review of its neuroprotective and behavioral properties. CNS Dmg Review 1998; 4: 149–64.
10. Schwarz M, Block F, Pergande G. NMDA-mediated muscle reluxant action offlupirtine in rats. NeuroReport 1994; 5: 1981–4.
11. Schwarz M, Schmitt T, Pergande G, Block F. NMDA and 2-adrenergic mechanisms are involved in the depressant action offlupirtine on spinal reflex in rats. Eur J Pharmacol 1995; 276: 247–55.
12. Szelenyi I et al. Mode of antinociceptive action of flupirtine in the rat. Br J Pharmacol 1989; 97: 835–42.
13. Szelenyi I et al. Pharmacological profile of flupirtine, a novel centrally acting non-opioid analgesic drug. Agents and Actions 1991; 32 (Suppl.): 119–23.
14. Van Tulder M. European Guidelines For the Management Of Acute Nonspecific Low Back Pain In Primary Care, 2004.
15. Worz R et al. Flupirtine in comparison with chlormezanone in chronic musculoskeletal back pain. Results of a multicenter randomized double-blind study. Fortschr Med 1996; 114 (35–36): 500–4.
2. Block F, Pergande G, Schwarz M. Flupirtine reduced funcional deficits and neuronal damage after global ischaemia in rats. Brain Res 1997; 754: 279–84.
3. Engel J. Flupirtine – a new centrally acting analgesic with unique chemical structure. Postgrad Med J 1987; 63 (Suppl. 3): 15–7.
4. Friedel НА, Fitton A. Flupirtine. A review of its farmacological properties and therapeutic efficacy in pain states. Dmgs 1993; 45: 548–69.
5. Komuber J et al. Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels. J Neural Transm 1999; 106: 857–67.
6. Mueller-Schwefe G. Flupirtine in Acute and Chronic Pain Associated with Muscle Tenseness. Results of a Postmarketing Surveillance Study. Fortschr Med 2003; 121: 3–10.
7. Muller WEG et al. Protection offlupirtine on p-amyloid-induced apoptisis in neuronal cells in vitro. J Neurochem 1997; 68: 2371–7.
8. Osbome NN et al. Protection of rabbit retina from ischemic injury by flupirtine. Invest. Ophtalm 1996; 37: 274–80.
9. Schuster G, Schwarz M et al. Flupirtine: A review of its neuroprotective and behavioral properties. CNS Dmg Review 1998; 4: 149–64.
10. Schwarz M, Block F, Pergande G. NMDA-mediated muscle reluxant action offlupirtine in rats. NeuroReport 1994; 5: 1981–4.
11. Schwarz M, Schmitt T, Pergande G, Block F. NMDA and 2-adrenergic mechanisms are involved in the depressant action offlupirtine on spinal reflex in rats. Eur J Pharmacol 1995; 276: 247–55.
12. Szelenyi I et al. Mode of antinociceptive action of flupirtine in the rat. Br J Pharmacol 1989; 97: 835–42.
13. Szelenyi I et al. Pharmacological profile of flupirtine, a novel centrally acting non-opioid analgesic drug. Agents and Actions 1991; 32 (Suppl.): 119–23.
14. Van Tulder M. European Guidelines For the Management Of Acute Nonspecific Low Back Pain In Primary Care, 2004.
15. Worz R et al. Flupirtine in comparison with chlormezanone in chronic musculoskeletal back pain. Results of a multicenter randomized double-blind study. Fortschr Med 1996; 114 (35–36): 500–4.
Авторы
В.В.Алексеев1, А.П.Рачин2, Е.В.Подчуфарова1
1 Московская медицинская академия им. И.М.Сеченова;
2 Смоленская государственная медицинская академия
1 Московская медицинская академия им. И.М.Сеченова;
2 Смоленская государственная медицинская академия
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.